Sentences with phrase «of acute leukemia in»

Thomas Look and colleagues use a type of genomic screen and identify abnormal HGF expression as a crucial factor for development of a class of acute leukemia in leukemia cell lines and clinical samples.

AML is one of the most deadly types of leukemia and the most common type of acute leukemia in adults; it increases in frequency as we age.

Not exact matches

In March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percenIn March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percenin first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.

The original pharmaceutical company was in the process of developing Annamycin, a drug that selectively kills highly resistant tumors, especially patients suffering from AML (Acute Myeloid Leukemia).

For the second time in 5 months, Juno Therapeutics has put a clinical hold on a Phase II trial of JCAR015 in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia due to patient deaths.

The Internet was buzzing all day with contradictory reports about Ephron's health, but it turns out she died Tuesday in New York of pneumonia brought on by acute myeloid leukemia, according to her son Jacob Bernstein.

Ikeme played no part in the team's promotion back to the elite division having been diagnosed with an acute Leukemia but was full of praises for Nuno Espirito Santos» side.

We found that a history of breastfeeding was associated with a reduction in the risk of acute otitis media, non-specific gastroenteritis, severe lower respiratory tract infections, atopic dermatitis, asthma (young children), obesity, type 1 and 2 diabetes, childhood leukemia, sudden infant death syndrome (SIDS), and necrotizing enterocolitis.

Among children, both acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) are usually diagnosed in their acute form.4 From 1975 to 2011, the incidence rate of leukemia increased in the United States by an annual average of 0.7 % for children and adolescents aged 0 to 19 years, 5 while in the European Union, the yearly increase in leukemia incidence between 1978 and 1997 averaged 0.6 %.6

Also benefitting will be The Leukemia & Lymphoma Society's Team in Training Program in memory of Jacquie Hirsch, a Williamsville native who lost her life to A.L.L. (Acute Lymphocytic Leukemia) September 6, 2008.

In a common subtype of acute myeloid leukemia, this abnormal activation of such self - renewing genes is apparently caused by structural modifications of the DNA packaging.

In 2011, after spending 8 years as an industry researcher, Arefolov took the seemingly backward step of becoming a postdoc in the lab of Harvard University chemistry professor Matthew Shair to work on developing a promising — and potentially lucrative — new approach to treating acute myeloid leukemiIn 2011, after spending 8 years as an industry researcher, Arefolov took the seemingly backward step of becoming a postdoc in the lab of Harvard University chemistry professor Matthew Shair to work on developing a promising — and potentially lucrative — new approach to treating acute myeloid leukemiin the lab of Harvard University chemistry professor Matthew Shair to work on developing a promising — and potentially lucrative — new approach to treating acute myeloid leukemia.

«Stem - cell researchers solve mystery of relapse in acute myeloid leukemia.»

Acute lymphoblastic leukemia is most frequent in children, adolescents and young adults, and it has a five - year survival rate of over 90 %.

None of the 4219 people studied were found to have a mutation in NPM1, the most common acute leukemia gene mutated in up to 40 per cent of cases.

Changes in the genetic code (mutations) that reduce TET2 function are found in 10 percent of patients with acute myeloid leukemia (AML), 30 percent of those with a form of pre-leukemia called myelodysplastic syndrome, and in nearly 50 percent of patients with chronic myelomonocytic leukemia.

«Protein isolated from baker's yeast shows potential against leukemia cells: Researchers performed in vitro trials to test the effect of L - asparaginase on acute lymphoblastic leukemia cells and published the results in Scientific Reports.»

However, genetic mutations in a gene called mixed lineage leukemia, or MLL, lead to an aggressive subtype of B - ALL known as MLL - rearranged, which is the most common type of acute lymphoblastic leukemia in infants.

After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

The gene (E2A) that codes for proteins with the properties of immunoglobulin enhancer binding factors E12 / E47 was mapped to chromosome region 19p13.2 - p 13.3, a site associated with nonrandom translocations in acute lymphoblastic leukemias.

Two different approaches are driving the buzz, and one of them got a big boost in August when the Food and Drug Administration approved a «living drug» to treat acute lymphoblastic leukemia (ALL) in children and young adults who've stopped responding to chemotherapy.

These chromosomal translocations are common in various types of leukemia, so the researchers examined two types: acute promyelocytic leukemia, which often carries a translocation between the PML and RARα genes; and acute myeloid leukemia, which can harbor a translocation between the MLL and AF9 genes.

It is activated in 50 to 80 percent of patients with acute myelogenous leukemia (AML), and in some, but not all cases, is associated with genetic mutations.

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical «signature» in blood - forming stem cells that predicts whether patients with acute myeloid leukemia (AML) will respond to chemotherapy.

A study by the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has found new interactions between two molecules involved in acute myeloid leukemia (AML), STAT3 and PRL - 3, which may offer a new therapeutic target for cancer treatment.

Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease.

Dr Matt Kaiser, Head of Research at Leukemia & Lymphoma Research, said: «Unfortunately there have been no significant improvements in survival rates for acute myeloid leukemia in the last two Leukemia & Lymphoma Research, said: «Unfortunately there have been no significant improvements in survival rates for acute myeloid leukemia in the last two leukemia in the last two decades.

A University of Colorado Cancer Center study published today in the journal Nature Genetics describes a newly - discovered, heritable genetic cause of acute lymphoblastic leukemia (ALL), namely mutation of the gene ETV6.

In both acute and chronic myelogenous leukemia, immature white blood cells in the bone marrow multiply out of controIn both acute and chronic myelogenous leukemia, immature white blood cells in the bone marrow multiply out of controin the bone marrow multiply out of control.

A patent application for a drug that could destroy the deadly childhood disease known as acute lymphoblastic leukemia — and potentially other cancers as well — has been submitted by researchers at Sandia National Laboratories, the University of Maryland and the MD Anderson Cancer Center in Houston.

«Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied.»

The findings of multiple in vivo preclinical studies published online in Blood Advances, a Journal of the American Society of Hematology (ASH), indicate that this therapy could potentially treat multiple cancers, including non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and acute myeloid leukemia (AML).

Studying acute promyelocytic leukemia cells under a microscope, the researchers noticed that they become abnormally large in the presence of arsenic.

With arsenic forcing the production of largely useless telomerase in cell lines that simulate acute promyelocytic leukemia, the chromosomes in cancer cells fuse together, causing the cell death that helps fight the cancer.

«Role of RNA binding protein in driving cancer, leukemia study reveals: Abnormally expressed in cancer cells, the protein was found to promote the proliferation of B cells in B - cell acute lymphoblastic leukemia.»

The new study, published March 14 in the Journal of Clinical Investigation, focused on a particularly aggressive form of B - cell acute lymphoblastic leukemia (B - ALL), the most prevalent type of leukemia in children and young adults.

Noelle Frey, MD, an assistant professor of Hematology - Oncology, will present results in 27 adult patients with acute lymphoblastic leukemia (ALL), identifying an optimal dose and infusion regimen that should improve treatment response while reducing potential for side effects.

His group was the first to publish findings of dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with autologous CD19 - targeted T cells.

In 2002, the Centers for Disease Control investigated several clusters of acute lymphatic leukemia in both Nevada and ArizonIn 2002, the Centers for Disease Control investigated several clusters of acute lymphatic leukemia in both Nevada and Arizonin both Nevada and Arizona.

The Kendall Park couple is no stranger to the work being done and exceptional care being provided at the Cancer Institute, as their son Brady Michael was treated there for acute undifferentiated leukemia before his passing in 2010, a few weeks shy of his second birthday.

People in an acute stage of the disease often develop severe anemia, because the leukemia cells, which live almost ten times as long as their normal counterparts, replace healthy cells in the bone marrow.

Gerrit Jan Schuurhuis of the Free University Medical Center in Amsterdam and his colleagues recently identified the new marker, called C - type lectin - like molecule - 1 or CLL - 1, in 92 percent of people with a form of acute myeloid leukemia.

Researchers can now tag individual malignant cells in the bone marrow of patients with acute myeloid leukemia.

Now a research team led by investigators in the Cancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC), has identified an inhibitor of the Pin1 enzyme that can address both of these challenges in acute promyelocytic leukemia (APL) and triple negative breast cancer.

List of abbreviations CNS: Central nervous system WHO: World Health Organization NF2: Neurofibromatosis 2 MA: Meningioangiomatosis ECOG: Eastern cooperative oncology group ALL: Acute lymphocytic leukemia CSF: Cerebrospinal fluid RIM: Radiation - induced meningiomas FISH: Fluoroscence in - situ hybridization CT: Computed tomography MRI: Magnetic resonance imaging

ATRA was first discovered for the treatment of acute promyelocytic leukemia (APL) in 1987.

The FDA approves Blincyto (blinatumomab) for use in the treatment of B cell acute lymphoblastic leukemia (ALL).

The FDA approves tretinoin, a differentiating agent related to vitamin A, for use in the treatment of acute promyelocytic leukemia.

A Phase 3 Open - label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

A Phase 3 Open - Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3 - ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First - line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation